Prognostic Factors and Treatment Outcomes in 93 Patients with Uterine Sarcoma from 4 Centers in Turkey

Durnali, Ayse; Tokluoglu, Saadet; Ozdemir, Nuriye; Inanc, Mevlude; Alkis, Necati; Zengin, Nurullah; Sonmez, Ozlem Uysal; Kucukoner, Mehmet; Anatolian Society of Medical Oncology

추천

검색

자료유형: 학술저널

저자정보: Durnali, Ayse (Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital) Tokluoglu, Saadet (Medical Oncology Department of Guven Hospital) Ozdemir, Nuriye (Medical Oncology Department of Ankara Numune Training and Research Hospital) Inanc, Mevlude (Medical Oncology Department of Erciyes University Faculty of Medicine) Alkis, Necati (Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital) Zengin, Nurullah (Medical Oncology Department of Ankara Numune Training and Research Hospital) Sonmez, Ozlem Uysal (Medical Oncology Department of Dr A.Y.Ankara Oncology Training and Research Hospital) Kucukoner, Mehmet (Medical Oncology Department of Dicle University Faculty of Medicine) Anatolian Society of Medical Oncology (Anatolian Society of Medical Oncology [ASMO])

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제5호

발행연도: 2012.1

수록면: 1,935 - 1,941 (7page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Introduction: Uterine sarcomas are a group of heterogenous and rare malignancies of the female genital tract and there is a lack of consensus on prognostic factors and optimal treatment. Objective and Methodology: To perform a retrospective evaluation of clinicopathological characteristics, prognostic factors and treatment outcomes of 93 patients with uterine sarcomas who were diagnosed and treated at 4 different centers from November 2000 to October 2010. Results: Of the 93 patients, 58.0% had leiomyosarcomas, 26.9% malignant mixed Mullerian tumors, 9.7% endometrial stromal sarcomas, and 5.4% other histological types. According to the last International Federation of Gynecology and Obstetrics (FIGO) staging, 43.0% were stage I, 20.4% were stage II, 22.6% were stage III and 14.0 % were stage IV. Median relapse free survival (RFS) was 20 months (95% confidence interval (CI), 12.4-27.6 months), RFS after 1, 2, 5 years were 66.6%, 44.1%, 16.5% respectively. Median overall survival (OS) was 56 months (95% CI, 22.5-89.5 months), and OS after 1, 2, 5 years was 84.7%, 78%, 49.4% respectively. Multivariate analysis showed that age ${\geq}60$ years and high grade tumor were significantly associated with poor OS and RFS; patients administered adjuvant treatment with sequential chemotherapy and radiotherapy had longer RFS time. Among patients with leiomyosarcoma, in addition to age and grade, adjuvant treatment with sequential chemotherapy and radiotherapy after surgery had significant effects on OS. Conclusion: Uterine sarcomas have poor progrosis even at early stages. Prognostic factors affecting OS were found to be age and grade.

#Uterine sarcoma #leiomyosarcoma #malignant mixed Mullerian tumor #prognostic factors #Turkey

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요